A pilot-scale system, enabled by an $82 million award from the FDA, aims to accelerate the development and production of mRNA technologies. The engineering challenges will be tackled by researchers at MIT as well as collaborators at Penn State University and Rensselaer Polytechnic Institute
Grand Challenge for Alternatives to Sugar
CBI Study Analyzes Contamination in Drug Manufacturing Plants
Applying Nanofluidics to Enhance Biomanufacturing
Healthcare / Medicine
Paper by CBI researchers helps define challenges with scaling of vaccine manufacturing
The team, led by CBI research scientist Donovan Guttieres published 'Models to inform neutralizing antibody therapy strategies during pandemics: the case of SARS-CoV-2' in the March 2021 volume of Antibody Therapeutics. This work was funded by the MIT-IBM Watson AI Lab and was previously featured in MIT news. Read the...
Modeling Framework to Evaluate Vaccine Strategies against the COVID-19 Pandemic
CBI's Biomanufacturing Group published "Modeling Framework to Evaluate Vaccine Strategies against the COVID-19 Pandemic" in the journal Systems as part of a special issue titled Systemic Thinking in Times of the COVID-19 Pandemic Crisis. The paper provides a systems-level modeling framework to guide the development of analytical tools aimed at informing time-critical...
NEWDIGS – Dynamic Dossier in the Cloud
Published on October 28th in Therapeutic Innovation & Regulatory Science, this article from CBI NEWDIGS addresses inefficiencies in the system and process of data sharing among stakeholders in the development, access, and use of drug therapies. It applies a Systems Engineering approach within a case study to propose a scalable...
CBI Study Analyzes Contamination in Drug Manufacturing Plants
A new study from the Center for Biomedical Innovation (CBI) published in Nature Biotechnology analyzes past incidents of viral contamination in the manufacturing of biopharmaceuticals and offers recommendations.
Interview with Gigi Hirsch, MD from Evidera
NEWDIGS is an exciting and innovative approach to developing solutions for systemwide impediments to biomedical innovation and patient care. The noncompetitive, collaborative environment encourages novel and fresh ideas and interactions to truly move the industry forward in positive ways. Dr. Debra Schaumberg, Vice President, Scientific Affairs, Real-World Evidence at Evidera...